PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
Niraparib in the PRIMA Trial
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer - Annals of Oncology
PRIMA Study | ZEJULA (niraparib)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial - The Lancet
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Frontiers | PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials | Oncology
PRIMA Study | ZEJULA (niraparib)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
PRIMA clinical trial: Universal Radical Cure of P. vivax malaria - Menzies
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆ - Annals of Oncology
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
PRIMA Study | ZEJULA (niraparib)
PRIMA Study | ZEJULA (niraparib)
State of the science: Contemporary front-line treatment of advanced ovarian cancer - Gynecologic Oncology
Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy G. A. Salles, J. - ppt download
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
EX-99.2 3 a15-4883_1ex99d2.htm EX-99.2 Exhibit 99.2 GRAPHIC Fourth-Quarter and Full-Year 2014 Results February 19, 2015 GRAPHIC Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of ...
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
First-line Maintenance and Future Directions - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
Presentación de PowerPoint
PRIMA Trial: Lessons Learned | tctmd.com
Pixium Vision announces positive long-term follow-up scientific data on PRIMA implant from Prima System French feasibility study
Prevention of incisional hernia with prophylactic onlay and sublay mesh reinforcement versus primary suture only in midline laparotomies (PRIMA): 2-year follow-up of a multicentre, double-blind, randomised controlled trial - The Lancet
